350 related articles for article (PubMed ID: 28260142)
1. The spectrum of Vogt-Koyanagi-Harada disease in Iran.
Hedayatfar A; Hosseini SM; Karimi N; Falavarjani KG; Badie N; Zameni M; Soheilian M
Int Ophthalmol; 2018 Apr; 38(2):443-449. PubMed ID: 28260142
[TBL] [Abstract][Full Text] [Related]
2. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey.
Tugal-Tutkun I; Ozyazgan Y; Akova YA; Sullu Y; Akyol N; Soylu M; Kazokoglu H
Int Ophthalmol; 2007; 27(2-3):117-23. PubMed ID: 16957877
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
Vukojević M; Vukojevic N; Vuković A; Rupčić B; Blažević M; Blažević A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):229-231. PubMed ID: 38651852
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
Yang P; Ren Y; Li B; Fang W; Meng Q; Kijlstra A
Ophthalmology; 2007 Mar; 114(3):606-14. PubMed ID: 17123618
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada disease in Hispanic patients.
Sukavatcharin S; Tsai JH; Rao NA
Int Ophthalmol; 2007; 27(2-3):143-8. PubMed ID: 17380271
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for Vogt-Koyanagi-Harada disease.
Sheu SJ; Kou HK; Chen JF
J Chin Med Assoc; 2003 Mar; 66(3):148-54. PubMed ID: 12779034
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
8. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
[TBL] [Abstract][Full Text] [Related]
10. Vogt-Koyanagi-Harada Syndrome in Brazilian Children.
Marquezan MC; Nascimento H; Dalbem D; Muccioli C; Belfort R
Ocul Immunol Inflamm; 2020 Apr; 28(3):402-408. PubMed ID: 31120768
[No Abstract] [Full Text] [Related]
11. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.
Khairallah M; Zaouali S; Messaoud R; Chaabane S; Attia S; Ben Yahia S; Hmidi K
Int Ophthalmol; 2007; 27(2-3):125-30. PubMed ID: 17203358
[TBL] [Abstract][Full Text] [Related]
13. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
[TBL] [Abstract][Full Text] [Related]
14. Clinical and multimodal imaging characteristics of acute Vogt-Koyanagi-Harada disease unassociated with clinically evident exudative retinal detachment.
Attia S; Khochtali S; Kahloun R; Ammous D; Jelliti B; Ben Yahia S; Zaouali S; Khairallah M
Int Ophthalmol; 2016 Feb; 36(1):37-44. PubMed ID: 25939987
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
16. Significant prognostic factors for Vogt-Koyanagi-Harada disease in the early stage.
Sheu SJ; Kou HK; Chen JF
Kaohsiung J Med Sci; 2004 Mar; 20(3):97-105. PubMed ID: 15124893
[TBL] [Abstract][Full Text] [Related]
17. BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis.
Agarwal A; Freund KB; Kumar A; Aggarwal K; Sharma D; Katoch D; Bansal R; Gupta V;
Retina; 2021 Apr; 41(4):774-783. PubMed ID: 32833410
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
20. Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases.
Usui Y; Goto H; Sakai J; Takeuchi M; Usui M; Rao NA
Graefes Arch Clin Exp Ophthalmol; 2009 Aug; 247(8):1127-32. PubMed ID: 19308440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
